Literature DB >> 24371652

Prolonged response of relapsed high grade serous ovarian carcinoma to the oral angiokinase inhibitor nintedanib in a patient with a germline BRCA1 mutation.

Han Hsi Wong1, Christine Parkinson1, Jonathan A Ledermann2, James D Brenton3, Michael Merger4, Ashley Shaw1, Aileen Patterson1, Mahmood Shafi1, Helena M Earl5.   

Abstract

► Nintedanib is an anti-angiogenic agent that has demonstrated activity in relapsed ovarian cancer. ► Our patient had prolonged response to nintedanib, allowing her to have potentially curative surgery 6 years after her diagnosis. ► The relationship between angiogenesis and BRCA mutation is worth exploring in ovarian cancer.

Entities:  

Keywords:  Angiogenesis; BIBF 1120; BRCA; Nintedanib; Ovarian cancer; VEGF

Year:  2012        PMID： 24371652      PMCID： PMC3862224          DOI： 10.1016/j.gynor.2012.10.003

Source DB:  PubMed          Journal:  Gynecol Oncol Case Rep        ISSN： 2211-338X


  9 in total

1.  Direct interaction between BRCA1 and the estrogen receptor regulates vascular endothelial growth factor (VEGF) transcription and secretion in breast cancer cells.

Authors:  Hideki Kawai; Huchun Li; Philip Chun; Shalom Avraham; Hava Karsenty Avraham
Journal:  Oncogene       Date:  2002-10-31       Impact factor: 9.867

2.  A phase 3 trial of bevacizumab in ovarian cancer.

Authors:  Timothy J Perren; Ann Marie Swart; Jacobus Pfisterer; Jonathan A Ledermann; Eric Pujade-Lauraine; Gunnar Kristensen; Mark S Carey; Philip Beale; Andrés Cervantes; Christian Kurzeder; Andreas du Bois; Jalid Sehouli; Rainer Kimmig; Anne Stähle; Fiona Collinson; Sharadah Essapen; Charlie Gourley; Alain Lortholary; Frédéric Selle; Mansoor R Mirza; Arto Leminen; Marie Plante; Dan Stark; Wendi Qian; Mahesh K B Parmar; Amit M Oza
Journal:  N Engl J Med       Date:  2011-12-29       Impact factor: 91.245

3.  Incorporation of bevacizumab in the primary treatment of ovarian cancer.

Authors:  Robert A Burger; Mark F Brady; Michael A Bookman; Gini F Fleming; Bradley J Monk; Helen Huang; Robert S Mannel; Howard D Homesley; Jeffrey Fowler; Benjamin E Greer; Matthew Boente; Michael J Birrer; Sharon X Liang
Journal:  N Engl J Med       Date:  2011-12-29       Impact factor: 91.245

4.  Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer.

Authors:  Jonathan A Ledermann; Allan Hackshaw; Stan Kaye; Gordon Jayson; Hani Gabra; Iain McNeish; Helena Earl; Tim Perren; Martin Gore; Mojca Persic; Malcolm Adams; Lindsay James; Graham Temple; Michael Merger; Gordon Rustin
Journal:  J Clin Oncol       Date:  2011-08-22       Impact factor: 44.544

5.  Vascular endothelial growth factor (VEGF) levels and mutation of the BRCA1 gene in breast cancer patients.

Authors:  B Tarnowski; A Chudecka-Głaz; B Górski; I Rzepka-Górska
Journal:  Breast Cancer Res Treat       Date:  2004-12       Impact factor: 4.872

6.  OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.

Authors:  Carol Aghajanian; Stephanie V Blank; Barbara A Goff; Patricia L Judson; Michael G Teneriello; Amreen Husain; Mika A Sovak; Jing Yi; Lawrence R Nycum
Journal:  J Clin Oncol       Date:  2012-04-23       Impact factor: 44.544

7.  BRCA1 plays a role in the hypoxic response by regulating HIF-1alpha stability and by modulating vascular endothelial growth factor expression.

Authors:  Hyo Jin Kang; Hee Jeong Kim; Jeong-Keun Rih; Thomas L Mattson; Kyu Won Kim; Chi-Heum Cho; Jennifer S Isaacs; Insoo Bae
Journal:  J Biol Chem       Date:  2006-03-16       Impact factor: 5.157

8.  Reduced cell death, invasive and angiogenic features conferred by BRCA1-deficiency in mammary epithelial cells transformed with H-Ras.

Authors:  Arunasalam Navaraj; Niklas Finnberg; David T Dicker; Wensheng Yang; Elizabeth M Matthew; Wafik S El-Deiry
Journal:  Cancer Biol Ther       Date:  2009-12-14       Impact factor: 4.742

9.  Ovarian cancer: opportunity for targeted therapy.

Authors:  Tomoko Tagawa; Robert Morgan; Yun Yen; Joanne Mortimer
Journal:  J Oncol       Date:  2011-12-22       Impact factor: 4.375
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.